I belong to a community of researchers at Cincinnati Children’s Hospital Medical Center, plus other institutions here and abroad, who are unwaveringly committed to finding cures for pediatric gastrointestinal (GI) diseases, including eosinophilic gastrointestinal disorders (EGID). This is especially important to me after meeting patients and their caregivers, witnessing the impact that EGID has on their lives and sharing their hope for a Food and Drug Administration (FDA)-approved therapy.
My research strives to improve diagnostic methods for children with GI diseases, such as EGID and inflammatory bowel disease. As a pediatric pathologist at Cincinnati Children’s, I help evaluate the efficacy of various therapies, including biologics, for pediatric patients who have EGID. I also participate in multi-institutional studies of pediatric inflammatory bowel disease.
I helped create the eosinophilic esophagitis histology scoring system (EoEHSS), which systematically evaluates esophageal biopsies obtained for eosinophilic esophagitis, the most common form of EGID. Some of the features evaluated correlate with symptoms and potentially provide new therapeutic endpoints.
Beginning in 2011, U.S. News & World Report named me one of the Top Doctors in Pathology. In 2020, I received the American Academy of Asthma, Allergy and Immunology (AAAAI) and American Partnership for Eosinophilic Disorders (APFED) award for the best EGID abstract at the AAAAI annual meeting.
BS: Fordham University, NY, 1972.
MD: Georgetown University, Washington, D.C., 1977.
Residency: Pathology, New York Hospital, NY, 1977-80; Pathology, Columbia-Presbyterian Medical Center, NY, 1980-83.
Fellowship: Research, New York Lung Association, Columbia-Presbyterian Medical Center, N.Y., 1983-85; Research, American Lung Association, Columbia-Presbyterian Medical Center, NY, 1985-87.
Certification: Pathology, 1981; Pediatric Pathology, 1991.
Pediatric gastrointestinal pathology; eosinophilic gastrointestinal diseases; biopsy analyses; primary study endpoints; novel therapies to treat eosinophilic esophagitis in children; disorders of bowel immunity; bowel motility disorders
Colorectal Disorders, Pathology, Eosinophilic Disorders
Pathology, Eosinophilic Disorders
Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis. New England Journal of Medicine. 2022; 387:2317-2330.
Mucosal microbiota associated with eosinophilic esophagitis and eosinophilic gastritis. Journal of Pediatric Gastroenterology and Nutrition. 2022.
Reply. Gastroenterology. 2022; 163:1720-1721.
International Consensus Recommendations for Eosinophilic Gastrointestinal Disease Nomenclature. Clinical Gastroenterology and Hepatology. 2022; 20:2474-2484.e3.
Harnessing artificial intelligence to infer novel spatial biomarkers for the diagnosis of eosinophilic esophagitis. Frontiers in Medicine. 2022; 9.
Using Human Induced Pluripotent Stem Cell-Derived Organoids to Identify New Pathologies in Patients With PDX1 Mutations. Gastroenterology. 2022; 163:1053-1063.e7.
S401 Dupilumab Improves Clinical, Symptomatic, Histologic, and Endoscopic Aspects of EoE, Regardless of Prior Swallowed Topical Steroid Use. American Journal of Gastroenterology. 2022; 117:e281-e281.
Management of eosinophilic esophagitis associated food impaction in Europe and the United States. Diseases of the Esophagus. 2022; 35.
Eosinophilic Gastrointestinal Disorders: A new Path. Pediatric and Developmental Pathology. 2022; 25:568-569.
Multicenter Cohort Study of Infliximab Pharmacokinetics and Therapy Response in Pediatric Acute Severe Ulcerative Colitis. Clinical Gastroenterology and Hepatology. 2022.
Margaret H. Collins, MD, Marc E. Rothenberg, MD, PhD10/25/2021
Patient Ratings and Comments
All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey